Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.

Objective: Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or MTX have been monitored in the British Society for Paediatric and Adolescent Rheumatology Biologics and New Drug Register. Here, we report the duration of etanercept use for the first 5 years of the register and reasons for discontinuation.

Methods: Disease subtype and activity, comorbidity, treatment efficacy and safety data were recorded.